Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the ...

Worldwide Healthcare Trust PLC - Annual Financial Report PR Newswire LONDON, United Kingdom, June 11 10 June 2025Worldwide Healthcare Trust PLC(the "Company") Annual Financial ...

Adolescents face significant barriers to obesity medication access, despite a surge in prescriptions. Discover the ...

While Americans understand the benefits of GLP-1 agonist medications, 83% of Americans are unwilling to pay more than $100 in ...

This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran ...

Previous clinical studies suggested that - when combined with changes to their diet, exercise and behavioural support - ...

Are you weening yourself off a compounded version of the drug? Considering switching insurers in order to keep your ...

New technology and drugs are transforming how doctors detect and treat silent liver disease MASLD before it leads to liver ...

When the Food and Drug Administration (FDA) approved Byetta (exenatide) in 2005, doctors thought it was just approving the first glucagon-like peptide-1 (GLP-1) agonist to treat Type 2 diabetes. But ...

Wegovy, which has been used for weight loss reasons, is not going to be covered ... this is for whatever the indication is, even though it is intended for weight loss, just to get around this?

When Novo Nordisk’s GLP-1 drug Wegovy was approved by the U.S. Food ... clinicians and patients as a breakthrough for weight loss treatment. This was the first drug approved for the indication that ...